Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Capricor Inc.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05126758CT.gov A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nervous System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Deramiocel (this asset) | Capricor Inc. | P3 | B · 60 |
| Ginkgolide | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BB |
| Guanfacine | Maimonides Medical Center | P4 | BB |
| Brexpiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | P3 | BB |
| D-Thioctic Acid | Ain Shams University | P4 | BB |
| 3-N-BUTYLPHTHALIDE | Qianfoshan Hospital | P4 | BB |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | BB |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | BB |
| Aspirin | Ipsen | P3 | BB |
+42 more in the Nervous System Disorder cohort
Other indications for Deramiocel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Duchenne Muscular Dystrophy | — | P3 | B · 62 |
| Muscular Dystrophy | — | P3 | B · 60 |
| Muscular Atrophy | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Deramiocel in Nervous System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/deramiocel-nervous-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →